G1 Therapeutics (GTHX) Investor Presentation - Slideshow

Trilaciclib - Trilaciclib is a first-in-class myelopreservation therapy designed to preserve bone marrow and immune system function from damage caused by chemotherapy[4, 14] - In Small Cell Lung Cancer (SCLC) trials, trilaciclib reduced chemotherapy-related toxicity and the need for rescue interventions, leading to significant improvements in patient experience, less neutropenia and anemia, and reduced G-CSF usage and transfusions[15] - In a patient survey, 88% of SCLC respondents reported that myelosuppression had a moderate to major impact on their life, with 63% noting fatigue as their biggest myelosuppressive issue[16] - Data from pooled SCLC trials showed that patients receiving trilaciclib experienced a significant reduction in the mean duration of severe neutropenia in cycle 1, from 4 days in the placebo group to 0 days in the trilaciclib group[19] - In metastatic triple-negative breast cancer (mTNBC), preliminary data showed that the median overall survival (OS) was 20.1 months for patients treated with trilaciclib plus gemcitabine/carboplatin (GC), compared to 12.6 months for those treated with GC alone[27] Rintodestrant - Rintodestrant (G1T48) is a potential best-in-class oral Selective Estrogen Receptor Degrader (SERD) for ER+, HER2- breast cancer[4, 37] - Phase 1 data showed that rintodestrant was well-tolerated, with ER occupancy ≥ 80% in doses ≥ 600 mg, and preliminary evidence of anti-tumor activity in a heavily pre-treated population[38] - The company is assessing the potential of rintodestrant in a Phase 1/2a program with approximately 100 patients enrolled by year-end 2020, with additional data expected in 4Q20[40] Lerociclib - Lerociclib is a differentiated oral CDK4/6 inhibitor with a potentially improved safety and tolerability profile compared to other marketed CDK4/6 inhibitors[4, 47] - In a Phase 1b/2 trial, lerociclib plus fulvestrant showed a 65.2% clinical benefit rate and a median progression-free survival of 15 months (immature) in 110 patients with HR+/HER2- advanced breast cancer[49] Market Opportunity - Approximately 1 million U S patients receive chemotherapy annually[6] - The company estimates that there are over 350,000 adjuvant breast cancer patients, over 500,000 colorectal cancer patients, and 20,000 metastatic triple-negative breast cancer patients in the U S, EU5, and Japan[31, 56]